|Description||Famitinib is a novel multi-targeted receptor tyrosine kinase inhibitor under development for cancer treatment. Famitinib is a structural analogue ofsunitinib, is a novel and potent multi-targeted RTK inhibitor that is currently undergoing phase II clinical trials in China for the treatment of renal cell carcinoma, gastrointestinal stromal tumours, pancreatic cancer, and nasopharyngeal carcinoma. Compared with sunitinib, famitinib exhibits superior inhibition activities against multiple RTKs.|
|Synonyms||Famitinib; SHR1020; SHR 1020; SHR-1020|
|Current Developer||Jiangsu Hengrui Medicine Co. Ltd. China|
Zimelidine dihydrochloride is a 5-HT reuptake inhibitor with selectivity over noradrenalin and dopamine uptake (IC50 = 0.33, 8.2 and 12 μM, respectively). Zimel...
CH100 is a Chinese herbal medicine. It is previously used in the treatment of human hepatitis C.
CDK2, a member of the eukaryotic S/T protein kinase family, catalyzes the phosphoryl transfer of ATP γ-phosphate to serine or threonine hydroxyl (denoted as S0/...
Glucagon, a peptide compound, is effective in increasing the glucose concentration in bloodstream and could be released by pancrea α cells.
AZD 2098 is a potent and selective CCR4 receptor antagonist (pIC50 = 7.8) used for the treatment of allergic rhinitis. CCR4 is a molecule that can drive the imm...
Sodium Monofluorophosphate is a competitive inhibitor of pyruvate kinase and alkaline phosphatase with Ki of 3.4 mM and 69 μM, respectively, which also irrevers...
Ribuvaptan is a vasopressin receptor antagonist originated by Bayer HealthCare Pharmaceuticals. Now, Ribuvaptan is still in phase I development for the treatmen...
Empagliflozin is a potent and selective SGLT-2 inhibitor with IC50 of 3.1 nM, exhibits >300-fold selectivity over SGLT-1, 4, 5 and 6.